{"id":813088,"date":"2025-02-13T16:29:56","date_gmt":"2025-02-13T21:29:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2024-results-above-company-revenue-guidance\/"},"modified":"2025-02-13T16:29:56","modified_gmt":"2025-02-13T21:29:56","slug":"nu-skin-enterprises-reports-fourth-quarter-and-full-year-2024-results-above-company-revenue-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2024-results-above-company-revenue-guidance\/","title":{"rendered":"Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results Above Company Revenue Guidance"},"content":{"rendered":"

<\/p>\n

Nu Skin Enterprises Reports Fourth Quarter and Full-year 2024 Results <\/b>Above Company Revenue Guidance<\/b><\/p>\n

Company provides initial outlook for Q1 and FY 2025<\/i><\/p>\n

PROVO, Utah–(BUSINESS WIRE<\/a>)–
\nNu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2024 results above its latest revenue guidance.<\/p>\n

Executive Summary
\n
<\/b>Q4 2024 vs. Prior-year Quarter<\/b><\/p>\n\n\n\n\n\n\n
\n

Revenue<\/b><\/p>\n<\/td>\n

\n

\n$445.6 million; (8.8)%<\/p>\n

    \n
  • \n(4.1)% FX impact or $(20.1) million<\/p>\n<\/li>\n
  • \nRhyz revenue $83.1 million; 27.7%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Earnings Per Share (EPS)<\/b><\/p>\n<\/td>\n

\n

\n$(0.73) or $0.38 excluding restructuring and other charges, compared to $0.15 or $0.37 excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

Customers<\/b><\/p>\n<\/td>\n

\n

\n831,972; (15)%<\/p>\n<\/td>\n<\/tr>\n

\n

Paid Affiliates<\/b><\/p>\n<\/td>\n

\n

\n144,874; (13)% or (12)% excluding an adjustment to eligibility requirements<\/p>\n<\/td>\n<\/tr>\n

\n

Sales Leaders<\/b><\/p>\n<\/td>\n

\n

\n36,912; (16)%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Executive Summary
\n
<\/b>2024 vs. 2023<\/b><\/p>\n\n\n\n
\n

Revenue:<\/b><\/p>\n<\/td>\n

\n

\n$1.73 billion; (12.0)%<\/p>\n

    \n
  • \n(3.8)% FX impact or $(76.1) million<\/p>\n<\/li>\n
  • \nRhyz revenue $286.6 million; 32.3%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Earnings Per Share (EPS):<\/b><\/p>\n<\/td>\n

\n

\n$(2.95) or $0.84 excluding restructuring and other charges, compared to $0.17 or $1.85 excluding inventory write-off and other charges<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u201cWe were pleased to beat our fourth quarter revenue guidance, generate sequential revenue growth and exceed our adjusted earnings as we materially completed our restructuring plan,” said Ryan Napierski, Nu Skin president and CEO. \u201cAs we look ahead to 2025, we anticipate improving business trends and a return to year-over-year growth in several of our markets but also anticipate continued economic challenges and poor consumer sentiment, particularly in Greater China and South Korea.<\/p>\n

\n\u201cThis year we will focus on strengthening our core Nu Skin business with the continued rollout of our enhanced sales performance compensation plan in several markets as well as accelerating growth in developing markets including Latin America,\u201d continued Napierski. \u201cWe are also excited for Prysm iO\u2122, an exclusive intelligent wellness device that will provide consumers with the nutritional insights needed to look, live and feel better. We anticipate the introduction later this year of this breakthrough technology will infuse energy and future growth for the nutrition side of the business. Also, we were pleased with the strategic transaction of Mavely for $250 million, which strengthened our balance sheet and underscored the value of Rhyz to incubate and scale meaningful business, as we continue to invest in and advance our Rhyz segments.\u201d<\/p>\n

Q4 2024 Year-over-year Operating Results<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

Revenue<\/b><\/p>\n<\/td>\n

\n

\n$445.6 million compared to $488.6 million<\/p>\n

    \n
  • \n(4.1)% FX impact or $(20.1) million<\/p>\n<\/li>\n
  • \nRhyz revenue $83.1 million; 27.7%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Gross Margin<\/b><\/p>\n<\/td>\n

\n

\n62.7% or 71.4% excluding inventory write-off compared to 72.1%<\/p>\n

    \n
  • \nNu Skin business was 67.5% or 76.6% excluding inventory write-off compared to 77.4%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Selling Expenses<\/b><\/p>\n<\/td>\n

\n

\n37.1% compared to 37.1%<\/p>\n

    \n
  • \nNu Skin business was 40.3% compared to 40.8%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

G&A Expenses<\/b><\/p>\n<\/td>\n

\n

\n27.1% compared to 29.7%<\/p>\n<\/td>\n<\/tr>\n

\n

Operating Margin<\/b><\/p>\n<\/td>\n

\n

\n(11.9)% or 7.7% excluding restructuring and other charges compared to 3.3% or 6.4% excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

Interest Expense<\/b><\/p>\n<\/td>\n

\n

\n$5.9 million compared to $7.4 million<\/p>\n<\/td>\n<\/tr>\n

\n

Other Income<\/b><\/p>\n<\/td>\n

\n

\n$1.1 million compared to $0.6 million<\/p>\n<\/td>\n<\/tr>\n

\n

Income Tax Rate<\/b><\/p>\n<\/td>\n

\n

\n37.5% or 36.6% excluding restructuring and other charges compared to 21.9% or 24.9% excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

EPS<\/b><\/p>\n<\/td>\n

\n

\n$(0.73) or $0.38 excluding restructuring and other charges compared to $0.15 or $0.37 excluding restructuring and other charges\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Stockholder Value<\/b><\/p>\n\n\n\n
\n

Dividend Payments<\/b><\/p>\n<\/td>\n

\n

\n$3.0 million<\/p>\n<\/td>\n<\/tr>\n

\n

Stock Repurchases<\/b><\/p>\n<\/td>\n

\n

\n$0.0 million<\/p>\n